Tag Archives: 3D cancer models

  • 0

3 Posters @ AACR 2017 in DC

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2017 AACR Conference in Washington D.C.

KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference.

GREENVILLE, SC, March 21, 2017– KIYATEC Inc. is pleased to announce that three abstracts have been accepted by the committee at the American Association for Cancer Research (www.aacr.org).  KIYATEC scientific and business development staff will be in attendance at the conference.  In addition to the poster presentations, also KIYATEC will be exhibiting at Booth 1556.  Stop by to learn more about our 10+ years of 3D cell culture experience and the latest 3D co-culture model development projects focused on immuno-oncology applications.

  •  Abstract #1923 / 24 – Paired isolation and expansion of CSC and CTC from primary small cell lung cancer patient tissue and blood using the 3DKUBE bioreactor platform | Monday Apr 3, 2017 8:00 AM – 12:00 PM | Location: Section 41 / Poster 24 (LINK)
  • Abstract #4834 / 24 – 3D modeling of immune cell interactions in breast cancer and prediction of immunotherapy response | Tuesday,
    Apr 4, 2017, 1:00 PM – 5:00 PMLocation: Section 39 / Poster 24 (LINK)
  • Abstract #4837 / 27 – Development of an in vitro 3D glioblastoma model system for patient-specific drug response profiling Tuesday,
    Apr 4, 2017 1:00 PM – 5:00 PM | Location: Section 39 / Poster 27 (LINK)
3D Cell Culture Models

3 Posters Accepted at AACR 2017 Washington DC


  • 0

KIYATEC & Mayo Clinic Collaborate to Fight Ovarian Cancer

Tags : 

KIYATEC AND MAYO CLINIC COLLABORATE TO FIGHT OVARIAN CANCER

Collaboration aims to validate the accuracy ex vivo 3D (EV3D) cell culture predictions against ovarian cancer patient outcomes

Greenville, S.C. | June 16, 2016 07:00 EDT – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced a collaboration with Mayo Clinic to combine their complementary technology platforms for ovarian cancer clinical care.

Mayo Clinic is actively enrolling patients in a clinical study led by principal investigator John Weroha, M.D., in which patient-derived xenografts (PDX) generate living tumor samples specific to each enrolled ovarian cancer patient. The study assesses whether those samples can help determine which chemotherapy is most effective to treat that individual ovarian cancer patient should they become platinum resistant. A limitation of any PDX model is that it typically takes six to nine months before data is produced.  For some patients that don’t respond at all to the initial treatment information is needed in just a few weeks, a challenge inherent to any clinical study of this sort – until now.

KIYATEC similarly uses living tumor samples specific to each ovarian cancer patient in its active research study with Greenville Health System (GHS), the first healthcare provider to partner with KIYATEC on this research.  The difference is that KIYATEC uses its 3D cell culture platform to generate patient specific drug response prediction data in just 7 days.  If the research collaboration is successful, KIYATEC’s technology would complement the Mayo approach and allow for more patients to be treated according to personalized drug response models.

 “This significantly advances KIYATEC’s goal to validate the accuracy of our cell culture predictions against patient outcomes, the gold standard for these kinds of comparisons,” said Hal Crosswell, M.D., KIYATEC’s Chief Medical Officer.

About KIYATEC

KIYATEC’s mission is to accurately predict patient response to cancer drugs using their living tumor cells in 3D culture, and to use those predictions to improve patient outcomes, reduce healthcare costs and increase success in drug development and clinical trials.  The company creates and utilizes live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials and clinical cancer diagnostic applications. 

For more information, please visit www.kiyatec.com or follow KIYATEC on Twitter (@KIYATEC).


  • 0

NCI Contract: Cancer Stem Cell / Lung Cancer Project

Tags : 

National Cancer Institute (NCI) Awards KIYATEC $1.725M to Develop Cancer Stem Cell (CSC) Expansion Technology 

Contract Funds 3D Cell Culture Technology Platform to Expand CSCs for Small Cell Lung Cancer (SCLC) Model Development

GREENVILLE, SC | October 22, 2015 – KIYATEC announced today the award of a Fast Track Phase I and Phase II Small Business Innovation Research (SBIR) Contract for $1.725M from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH).  The overall goal of the contract is to develop culture systems which can grow and maintain the rare population of malignant cells referred to by some as cancer stem cells, which are believed to lead to therapy resistance, relapse and death from metastatic disease.  KIYATEC’s focus is small cell lung cancer (SCLC), one of the deadliest forms of cancer today with little advancement in treatments in 4 decades.

NCI Cancer Stem Cell Contract Award


  • 0

$2M NCI Contract To Advance Predictive Cancer Diagnostics

Tags : 

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development

GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.

Predictive 3D Cancer Diagnostics


x Shield Logo
This Site Is Protected By
The Shield →